Skip to main content

Table 3 Medications currently prescribed as acute or preventive migraine treatment for ≥5% of patients with episodic and chronic migraine: physician-reported data

From: Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme

Medication Cohort Total
(n = 977)
p-value
Episodic migraine (n = 923) Chronic migraine (n = 54)
Acute treatment
 Eletriptan 91 (9.9) 2 (3.7) 93 (9.5) 0.134a
 Naratriptan 133 (14.4) 11 (20.4) 144 (14.7) 0.230a
 Sumatriptan 162 (17.6) 7 (13.0) 169 (17.3) 0.386a
 Rizatriptan 148 (16.0) 14 (25.9) 162 (16.6) 0.057a
 Zolmitriptan 113 (12.2) 6 (11.1) 119 (12.2) 0.805a
 Loxoprofen 275 (29.8) 18 (33.3) 293 (30.0) 0.581a
 Diclofenac 48 (5.2) 4 (7.4) 52 (5.3) 0.525b
Preventive treatment
 Lomerizine 131 (14.2) 13 (24.1) 144 (14.7) 0.046a
 Valproic acid 116 (12.6) 17 (31.5) 133 (13.6) < 0.001a
 Amitriptyline 61 (6.6) 8 (14.8) 69 (7.1) 0.048b
  1. Data are n (%)
  2. aChi-squared test
  3. bFisher’s exact test
\